Monday, October 27

Money

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its…

However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and…

© 2025 The Money Times. All rights reserved